摘要
Since the initial coronavirus disease 2019(COVID-19)outbreak in China in December 2019,the infection has now become the biggest medical issue of modern medicine.Two major contributors that amplified the impact of the disease and subsequently increased the burden on health care systems were high mortality among patients with multiple co-morbidities and overcapacity of intensive care units.Within the gastroenterology-related community,particular concern was raised with respect to patients with inflammatory bowel disease(IBD),as those patients are prone to opportunistic infections mainly owing to their immunosuppressive-based therapies.Hence,we sought to summarize current knowledge regarding COVID-19 infection in patients with IBD.Overall,it seems that IBD is not a comorbidity that poses an increased risk for COVID-19 acquisition,except in patients treated with 5-aminosalicylates.Furthermore,outcomes of the infected patients are largely dependent on therapeutic modality by which they are treated,as some worsen the clinical course of COVID-19 infection,whereas others seem to dampen the detrimental effects of COVID-19.Finally,we discussed the present and the future impact of COVID-19 pandemic and concomitantly increased health care burden on IBD-management.
